INNOVATIVE CELLULAR THERAPEUTICS
Innovative Cellular Therapeutics Co.,Ltd. is a Shanghai-based biotechnology company engaged in research and development of cell therapy.
INNOVATIVE CELLULAR THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Market Research Therapeutics
Founded:
2009-08-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.sidansai.com
Total Employee:
11+
Status:
Active
Contact:
+86 (021) 5895 9719
Total Funding:
28.6 M USD
Technology used in webpage:
SPF SSL By Default GoDaddy DNS Gravatar Profiles GoDaddy Lightspeed Cache Alibaba HiChina DNS Tengine Baidu Cloud
Similar Organizations
GeneQuantum Healthcare
GeneQuantum Healthcare is a high-tech company that focuses on the research and development of innovative Bio-therapeutics.
GenFleet Therapeutics
GenFleet Therapeutics is a biotechnology developer and researcher of molecular pharmaceuticals targeting cancer treatments.
Hummingbird Bioscience
Hummingbird Bioscience focuses on the discovery and early development of oncology drugs.
Current Employees Featured
Founder
Investors List
Qianhai LH Ventures
Qianhai LH Ventures investment in Series C - Innovative Cellular Therapeutics
Witruth Capital
Witruth Capital investment in Series B - Innovative Cellular Therapeutics
ShenZhen GTJA Investment Group
ShenZhen GTJA Investment Group investment in Series B - Innovative Cellular Therapeutics
Volcanics Venture
Volcanics Venture investment in Series B - Innovative Cellular Therapeutics
SBCVC
SBCVC investment in Series B - Innovative Cellular Therapeutics
More informations about "Innovative Cellular Therapeutics"
斯丹赛公司怎么样-上海斯丹赛生物官方网站
Larry (Lei) Xiao, Ph.D. Chairman, Chief Executive Officer, and Chief Scientific Officer. Read BioSee details»
上海斯丹赛生物技术有限公司 | LinkedIn
上海斯丹赛生物技术有限公司由「国家杰出青年基金」获得者肖磊博士于2009年8月创立，定位于全球细胞治疗领航者，致力于服务科技创新和人类 ...See details»
上海斯丹赛生物官方网站 - sidansai.com
斯丹赛生物技术有限公司定位于全球细胞治疗领航者，致力于服务科技创新和人类健康事业。在细胞治疗、干细胞和基因编辑等领域，斯丹赛达到了国际领先水平，申报了30余项美国、中国、 …See details»
SIDANSAI Biotechnology - Scientist.com
SIDANSAI Biotechnology is a high-tech company mainly focusing on the development of novel technologies and new products on stem cell and molecular biology. Specialties include TALEN …See details»
Innovative Cellular Therapeutics Co., Ltd. - synapse.zhihuiya.com
Www.sidansai.com. 上海斯丹赛 ... All responses were confirmed by an independent third-party imaging contract research organization. Results: 13 subjects have been enrolled to dose level …See details»
Sidansai Biotechnology - Overview, News & Similar companies
Who is Sidansai Biotechnology. SIDANSAI Biotechnology CO.,LTD is a high-tech company mainly focusing on the development of novel technologies and new products on stem cell and …See details»
Innovative Cellular Therapeutics - Crunchbase
Innovative Cellular Therapeutics Co.,Ltd. is a Shanghai-based biotechnology company engaged in research and development of cell therapy.See details»
上海斯丹赛生物技术有限公司 - 百度百科
斯丹赛拥有成熟稳定的 人类胚胎干细胞 、 诱导性多能干细胞 (ips)技术平台，拥有自主产生的多株人类胚胎干细胞系以及多物种的 ips细胞 系；此外，斯丹赛还具有一流的talen技术平台，talen …See details»
Anti-CD19 chimeric antigen receptor T-cell therapy for adult ...
A .gov website belongs to an official government organization in the United States . Secure .gov websites use HTTPS ... LX and ZW are cofounders of Innovative Cellular Therapeutics Co., …See details»
Leading Chinese CAR-T cell therapy provider SiDanSai changes …
May 13, 2016 Meanwhile, a SiDanSai delegation consisting of Dr. Jimmy Wei (CEO), Dr. Zhao Wu (President of Research and Development), and Dr. David Kapitula (Director of …See details»
Xin Wu - Sr. Director of Clinical Research - Shanghai SIDANSAI ...
Clinical Research Director at Daiichi Sankyo · More than 15 years of experience in clinical management role both in pharmaceutical and medical device industry.<br>Ø Experienced …See details»
Innovative Cellular Therapeutics - sidansai.com
[临床进展英文] The 43rd Annual Meeting of European Group for Blood and Marrow Transplantation (EBMT 2017) 2017-03-31See details»
Innovative Cellular Therapeutics Co., Ltd. Release: Leading
SHANGHAI, May 13, 2016 /PRNewswire/ -- SiDanSai Biotechnology Co., Ltd. (SiDanSai) has recently released its first batch of Chimeric Antigen Receptor T (CAR-T) clinical data after …See details»
细胞治疗公司斯丹赛获超 4000 万美元 C 轮融资，实体瘤 CAR-T 获 …
9月6日，上海斯丹赛生物技术有限公司（以下简称“斯丹赛”）宣布完成超4千万美元C轮融资，本轮融资由鼎晖VGC（鼎晖创新与成长基金）领投，另有多家投资机构跟投。 此外，美国FDA于8 …See details»
全站导航-上海斯丹赛生物官方网站 - sidansai.com
全站导航上海斯丹赛生物技术有限公司公司新闻See details»
Potent Anti-leukemia Activities of Chimeric Antigen Receptor
Jul 1, 2017 8 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. [email protected] [email protected]. …See details»
Anti-CD19 chimeric antigen receptor T-cell therapy for adult ...
Dec 23, 2016 1. Introduction. The Philadelphia chromosome (Ph) is the most common cytogenetic abnormality associated with adult acute lymphoblastic leukemia (ALL), occurring in …See details»
A One-Step System for Convenient and Flexible Assembly of
1 From Innovative Cellular Therapeutics Co., Ltd, (formerly SiDanSai Biotechnology Co., Ltd), Shanghai 201203, China. PMID: 27604899 PMCID: PMC5050533 DOI: …See details»
car-t免疫疗法技术优势-上海斯丹赛生物官方网站
除肠癌产品外， 前列腺癌产品也取得了良好的初步临床疗效，且安全性良好。 以 pap为靶点的前列腺癌产品pap19cart，正在推进国内irb临床试验，已回输的5例受试者中有4例达到了psa应 …See details»